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Case Report
AbstractWe present the unusual case of malignant chondroid syringoma (MCS) in a64-year-old male with recurrent nodular skin lesions and visceral metastases. Thepatient underwent repeated excisions, with eventual development of widespreadnodules and multiple pulmonary and hepatic nodules. Systemic chemotherapy wasplanned. MCS is a very rare skin adnexal tumor of the sweat glands with onlyaround 50 cases reported worldwide. To the authors’ knowledge, this is the firstreported case of MCS with a multifocal presentation and mucosal involvement.
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1. IntroductionSkin cancer causes significant morbidity worldwide.1However, apocrine-eccrine carcinomas are rare, with areported incidence rate of 2.6 per 1 million person-years. Still, these adnexal neoplasms are associated witha prolonged course and a poor prognosis in the presenceof metastatic disease, with a 5-year relative survival rateof 51%.2,3Malignant chondroid syringoma (MCS), also calledmalignant mixed tumor of the skin, is an extremelyuncommon eccrine sweat gland neoplasm withepithelial and mesenchymal components. Due to theabsence of a distinct clinical presentation, it is difficult todistinguish from other cutaneous tumors.4
2. Case presentationWe present the case of a 64-year-old male withrecurrent nodular skin lesions on his right arm. Thepatient underwent repeated excisions, followed by wideexcision with axillary lymph node dissection. A 10-cmfirm, lobulated mass with skin ulceration and muscleinvolvement was removed. Microscopic examinationrevealed infiltrating nests of medium to large epithelialcells embedded in a chondromyxoid matrix with few
scattered plasmacytoid myoepithelial cells (see Figure1). There was brisk mitosis as well as large areas oftumor necrosis. All axillary lymph nodes were negativefor tumor. The final histopathologic diagnosis wasmalignant chondroid syringoma. However, the patientwas lost to follow-up.
Figure 1: (1000x magnification). Cuboidal to polygonaltumor cells embedded in a chondromyxoid matrix, withmoderate to abundant eosinophilic cytoplasm, round toovoid nuclei, and prominent nucleoli.
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The patient’s surgery was closely followed by theappearance of multiple similar-looking nodules over thescalp, face (including the buccal mucosa), trunk, rightupper extremity, and right foot (see Figure 2). Thepatient also developed hepatomegaly accompanied byprogressive weight loss and anorexia. Subsequentimaging studies revealed multiple pulmonary andhepatic nodules. The patient was then referred forpalliative chemotherapy. At the time of consult, he hadan Eastern Cooperative Oncology Group (ECOG)performance status of 2 and was advised a trial ofdoxorubicin-based chemotherapy. However, his clinicalcondition rapidly deteriorated and he eventually expiredbefore starting treatment.
Figure 2:Multiple firm, erythematous nodules withindurated edges and central ulceration (scalp).
3. DiscussionChondroid syringoma is a rare type of syringoma thathistologically resembles benign mixed tumors of thesalivary glands.5 Its cancerous subtype, malignantchondroid syringoma, is the rarest variant, with anestimated incidence of <0.005%6. In contrast to itsbenign counterpart, MCS is more common in women,affects a wider age range, and usually involves the trunkand extremities.7 Malignant lesions are usually muchlarger and appear as firm, circumscribed, asymmetricalskin nodules. They may progress very slowly, with latemetastatic spread.4,6Due to the lack of a distinct clinical presentation, MCSmay be confused with various skin tumors, makinghistopathological and immunohistochemicalexamination of paramount importance due todifferences in its treatment and prognosis.8 Uponliterature review, MCS has been most commonlymisdiagnosed as benign chondroid syringoma,unclassified benign sweat gland tumor, and basal cellcarcinoma. Histopathologically, MCS consists of clustersof epithelial cells and ductal structures with interveningchondromyxoid matrix and scattered myoepithelialcells. The most reliable histologic features that favormalignancy include cellular atypia, nuclear
pleomorphism, increased mitotic activity, focal necrosis,infiltrative borders, invasion of adjacent soft tissues,satellite tumor nodules, and metastasis.5,8Immunohistochemical features include reactivity forepithelial markers such as cytokeratin (CK), epithelialmembrane antigen (EMA), and carcinoembryonicantigen (CEA), as well as mesenchymal markers likevimentin, S-100, neuron-specific enolase (NSE), and glialfibrillary acidic protein (GFAP), similar to their salivarygland counterparts.9MCS is an aggressive tumor with a significant risk formetastasis via hematogenous and lymphatic spread.4,7 Itcarries a mortality rate of approximately 25%.10 It tendsto follow an unpredictable course, with approximately50% presenting with local recurrences, 42% with nodalmetastases, and 40% with distant metastases. The mostcommonly identified site of distant metastasis was thelung, followed by bone and brain.11 Due to the smallnumber of reported cases, prognostic factors are stilldifficult to establish, but these likely include size,histological type, lymph node involvement, and distantmetastasis.After a thorough literature search, 51 previous cases ofMCS were retrieved.4,6-8,10-54 Including the present case,the age range was from 13 to 89 years, with a medianage of 54 years. There was no particular agepredilection, but there were slightly more cases in thefourth and seventh decades. More females were affected(58%). The most commonly affected primary sites werethe extremities (54%), followed by the head and neckregion (29%) and the trunk (17%). The present case isparticularly exceptional because of the multifocalpresentation and the presence of mucosal involvement.Most cases had recurrent disease (60%), and nodalinvolvement was present in 37%. Distant metastaseswere documented in 37% of all cases and in 71% ofrecurrent cases, most commonly affecting the lungs(24%), followed by the central nervous system (10%),pleura (10%), bone (8%), and liver (6%). These data arequite consistent with previously published literature.However, it is more difficult to draw conclusionsregarding mortality data as most cases had shortfollow-up times and not all authors mentioned theoutcomes of their patients. Nevertheless, 17% of thecases included in this review died of progressive cancerdisease. Surgery was the most widely utilized first-linetreatment option, followed by radiotherapy andchemotherapy.At present, there are no established guidelines for thetreatment of apocrine-eccrine carcinomas, particularlyfor those with distant metastases. Complete surgicalexcision of the primary tumor with wide margins anddissection of involved lymph nodes is the mainstay oftreatment for localized disease, as incomplete removalcould result in recurrences.4,19,24 Adjuvant radiotherapyand chemotherapy may also be recommended, but their
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definite roles are currently not yet well established asthe rarity of this type of tumor precludes clinicaltrials.6,42 Previous reports suggest a possible survivaladvantage in patients with aggressive tumors receivingadjuvant radiotherapy.16,18,24 In particular, bonemetastases and spinal cord compression have beenshown to be responsive to local radiotherapy.6,41 On theother hand, the benefit of combination chemotherapy inmetastatic disease has not yet been confirmed.Chemotherapeutic regimens that have been triedinclude: (1) Cyclophosphamide, vincristine, doxorubicin,dacarbazine (CYVADIC regimen) 31,51; (2) Cyclophospha-mide, vincristine, doxorubicin48; (3) Cyclophosphamide,vincristine, dactinomycin6; (4) Cyclophosphamide,vincristine, vinblastine39; (5) Cisplatin, etoposide33; (6)Cisplatin, paclitaxel31; (7) 5-fluorouracil, cisplatin48; (8)5-fluorouracil, leucovorin, cyclophosphamide, doxorubi-cin33; (9) Tegafur, gimeracil, oteracil potassium25; and(10) Intralesional methotrexate35. However, no lastingclinical response has been observed with most of theseregimens except for the CYVADIC protocol, with thetreated patient still alive after 5 years of follow-up.51
4. ConclusionTo the authors’ knowledge, this is the first reported caseof malignant chondroid syringoma with a multifocalpresentation and mucosal involvement. Because thedisease has no distinct clinical presentation, itsdiagnosis relies on its characteristic histopathologicaland immunohistochemical findings. Complete surgicalexcision is the cornerstone of therapy for localizeddisease, while the role of other treatment modalitiessuch as radiotherapy and chemotherapy has not yetbeen well established.
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